European Trial of Pirfenidone in BOS, A European Multi-center Study
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in
bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.
Randomized double blinded, placebo controlled study. Eligible patients are to be randomized
in a 1:1 ratio to receive either Pirfenidone 2403 mg/d or the matching placebo treatment for
6 months.
Primary objective To evaluate the effect of Pirfenidone on the change in FEV1 in liters over
6 months in lung transplant recipients with bronchiolitis obliterans syndrome.